Source comparison
Melanotan-1 Clinical Trials 2026: Phase II Endpoints Comparison
Melanotan-1 clinical trials 2026 span multiple indications, each with distinct primary endpoints and regulatory pathways. Understanding these differences clarifies what "success" means in each context and how trial design shapes interpretation of results. | Tr
This comparison does not assign a generated winner or score.
- Melanotan-1 clinical trials 2026 span multiple indications, each with distinct primary endpoints and regulatory pathways. Understanding these differences clarifies what "success" means in each context and how trial design shapes interpretation of results.
- | Trial Name | Indication | Primary Endpoint | Comparator Arm | Expected Completion | Regulatory Pathway | Bottom Line ||—|—|—|—|—|—|| VITISTIM-2026 | Vitiligo repigmentation | >75% repigmentation in target lesions at 12 months | Narrowband UVB phototherapy alone | Q4 2026 | EMA orphan drug designation pathway | Combination therapy showing 21% absolute improvement over standard of care at interim. If Phase III confirms, this becomes first approved vitiligo pharmacotherapy || CUV039 Pediatric Extension | EPP photoprotection in children | Median increase in pain-free sun exposure hours per day | Baseline (pre-treatment) sun tolerance | Q4 2026 | FDA post-market pediatric study requirement | Already approved in adults. Pediatric data will extend label if safety profile holds, expanding eligible patient population by ~40% || PHOTOGUARD-AU | Polymorphous light eruption prevention | Reduction in eruption episodes during 6-month treatment vs placebo | Placebo implant | Q2 2027 | TGA innovativ
- The comparison makes clear that Melanotan-1 clinical trials 2026 are not a single unified program. They represent parallel investigator-led and sponsor-driven efforts targeting mechanistically related but clinically distinct endpoints. Only VITISTIM-2026 and CUV039 are registration-directed trials intended to support regulatory submissions; the others are hypothesis-generating studies that may or may not lead to Phase III programs depending on results.